Experimental vaccine combo aims to supercharge immune attack on bile duct cancer
NCT ID NCT06564623
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase study tests a personalized peptide vaccine (mBTCvax) combined with two immunotherapy drugs (durvalumab and tremelimumab) in 25 adults with advanced biliary tract cancer. The goal is to see if the combination is safe and can boost the immune system's ability to target cancer cells. Participants must have already received standard chemotherapy and have tumors with specific genetic mutations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- personalized mutant peptide vaccine (mBTCvax) with Poly-ICLC adjuvant, durvalumab, and tremelimumab
- What this could lead to
- If it works, this could point toward a new treatment option that helps the immune system fight biliary tract cancer more effectively.
- What could go wrong
- This is a very early, small Phase 1 pilot study with only 25 participants. The combination may cause serious side effects, and it is unknown if it will improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
SKCCC Johns Hopkins Medical Institution
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.